CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) CFO Robert Stefanovich sold 2,743 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $21,944.00. Following the completion of the sale, the chief financial officer owned 280,371 shares in the company, valued at $2,242,968. This represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Robert Stefanovich also recently made the following trade(s):
- On Thursday, March 12th, Robert Stefanovich sold 38,700 shares of CryoPort stock. The shares were sold at an average price of $7.76, for a total transaction of $300,312.00.
CryoPort Stock Down 2.9%
Shares of NASDAQ:CYRX opened at $8.12 on Thursday. The firm has a market capitalization of $404.86 million, a PE ratio of 6.15 and a beta of 1.69. CryoPort, Inc. has a twelve month low of $4.63 and a twelve month high of $11.45. The company has a 50-day moving average price of $9.14 and a two-hundred day moving average price of $9.35.
Hedge Funds Weigh In On CryoPort
A number of large investors have recently modified their holdings of the company. Corient Private Wealth LLC purchased a new position in CryoPort during the fourth quarter valued at approximately $113,000. Invesco Ltd. increased its holdings in CryoPort by 19.3% during the 4th quarter. Invesco Ltd. now owns 96,541 shares of the company’s stock worth $927,000 after acquiring an additional 15,607 shares during the period. XTX Topco Ltd purchased a new stake in CryoPort in the 4th quarter worth approximately $424,000. Tudor Investment Corp ET AL lifted its stake in CryoPort by 3.3% in the 4th quarter. Tudor Investment Corp ET AL now owns 300,414 shares of the company’s stock worth $2,884,000 after purchasing an additional 9,690 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new position in CryoPort in the 4th quarter valued at $97,000. 92.90% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
CYRX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. Wall Street Zen lowered CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Needham & Company LLC lifted their price target on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CryoPort has a consensus rating of “Moderate Buy” and an average target price of $12.94.
Check Out Our Latest Analysis on CYRX
About CryoPort
CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.
CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.
Read More
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.
